Huntington's Disease News and Research

Latest Huntington's Disease News and Research

Positive results from Alnylam’s ALN-PCS Phase I trial on severe hypercholesterolemia

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today positive results from its Phase I clinical trial of ALN-PCS, an RNAi therapeutic targeting PCSK9 for the treatment of severe hypercholesterolemia.

21 Apr 2012

Huntington’s disease may protect against cancer: Study

Dr Jianguang Ji, Lund University, and Skåne University Hospital, Malmö, Sweden, and colleagues investigated data from the Swedish Cancer Registry. Researchers analyzed Swedish hospital data from 1969 to 2008. They found 1,510 patients with Huntington's disease. During the study period, 91 of those patients subsequently developed cancer. The authors said that was 53% lower than the levels expected for the general population.

15 Apr 2012

Technique developed to identify rogue clustering proteins in brain diseases

Australian researchers have developed a novel technique that tracks proteins “behaving badly” and may have found a way that leads to new treatments for brain disease. The team believes the discovery could help in the development of drugs to treat diseases such as Alzheimer's, Parkinson's and Huntington's.

19 Mar 2012

Novel technique rapidly identifies and tracks location of diseased proteins inside cells

A research team led by the University of Melbourne, Australia, has developed a novel technique that tracks diseased proteins behaving badly by forming clusters in brain diseases such as Huntington's and Alzheimer's.

19 Mar 2012

Alnylam commences dosing in ALN-TTR02 Phase I clinical trial for TTR-mediated amyloidosis

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has initiated dosing in its Phase I clinical trial with ALN-TTR02, an RNAi therapeutic targeting the transthyretin (TTR) gene for the treatment of TTR-mediated amyloidosis (ATTR). The study is aimed at evaluating the safety and tolerability of ALN-TTR02 in healthy volunteers.

19 Mar 2012

GABA neurons could help restore muscle coordination deficits of Huntington's

Huntington's disease, the debilitating congenital neurological disorder that progressively robs patients of muscle coordination and cognitive ability, is a condition without effective treatment, a slow death sentence. But if researchers can build on new research reported this week in the journal Cell Stem Cell, a special type of brain cell forged from stem cells could help restore the muscle coordination deficits that cause the uncontrollable spasms characteristic of the disease.

16 Mar 2012

Measuring wellbeing in Huntington’s disease

The new tool, the first Huntington’s disease-specific quality of life instrument of its kind, aims to fully capture the impact of this complex disease on the everyday life of sufferers. By using this new tool to more accurately measure the impact of Huntington’s and also any effect of therapeutic interventions, scientists will be in a better position to evaluate the usefulness of interventions on patients’ everyday quality of life to see if there is actually a practical benefit. It is hoped that in this way, this tool will lead to more effective treatments.

8 Mar 2012

Nuvilex overcomes fundamental challenges faced in stem cell therapy

Nuvilex, Inc., an emerging biotechnology provider of cell and gene therapy solutions, released information today about the company's cell encapsulation technology and the breakthrough in stem cell research which overcomes specific fundamental challenges faced in stem cell therapy—host rejection and migration of implanted cells away from the target site.

5 Mar 2012

WUSTL scientists to decode DNA of 99 patients with rare diseases

Rare genetic diseases, long overlooked because they affect relatively few people, are getting new attention. Scientists at Washington University School of Medicine in St. Louis are reaching out to patient advocacy groups and offering to decode the DNA of 99 patients with rare diseases to help find the genetic alterations responsible for their illnesses.

3 Mar 2012

Researchers refute widely accepted hypothesis about causative step in ALS

In science, refuting a hypothesis can be as significant as proving one, all the more so in research aimed at elucidating how diseases proceed with a view toward preventing, treating, or curing them. Such a discovery can save scientists from spending precious years of effort exploring a dead end. In a study published in the Proceedings of the National Academy of Sciences, Munich-based researchers refute a widely accepted hypothesis about a causative step in neurodegenerative conditions.

1 Mar 2012

Researchers discover mechanism by which lead alters nerve cells in the brain

Exposure to lead wreaks havoc in the brain, with consequences that include lower IQ and reduced potential for learning. But the precise mechanism by which lead alters nerve cells in the brain has largely remained unknown.

1 Mar 2012

Helmholtz Association grant for research on diseases caused by protein misfolding

Professor Erich Wanker of the Max Delbr-ck Center for Molecular Medicine (MDC) Berlin-Buch and of the Excellence Cluster Neurocure is to receive EUR 675 000 in funding from the Helmholtz Association over the next two years. The grant shall be used to accelerate the search for active agents to treat diseases that are caused by protein misfolding. These include Alzheimer's and Parkinson's.

24 Feb 2012

New drug for Huntington's disease might operate via previously unknown mechanisms of action

A study from Karolinska Institutet in Sweden shows that a new drug for Huntington's disease - pridopidine or dopamine stabiliser ACR16 - might operate via previously unknown mechanisms of action. Researchers have found that at very low concentrations, ACR16 binds to the sigma-1 receptor, a protein in the brain important to neuronal function and survival.

24 Feb 2012

New Huntington's drug might operate via previously unknown mechanisms of action

24 Feb 2012

New potential therapy for Huntington disease

Medical researchers at the University of Alberta have discovered a promising new therapy for Huntington disease that restores lost motor skills and may delay or stop the progression of the disease based on lab model tests, says the lead researcher.

14 Feb 2012

Alnylam commences underwritten public offering of 7,000,000 shares of common stock

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced that it has commenced an underwritten public offering of 7,000,000 shares of its common stock. All of these shares are being sold by Alnylam.

14 Feb 2012

New cERD method can detect RNAi activity in biological fluids

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that its scientists have discovered a novel method for monitoring RNAi activity in blood samples, representing a potential major advance for future development of RNAi therapeutics, other therapeutic modalities, and diagnostics.

10 Feb 2012

Neuralstem announces registered direct placement of 5,200,000 shares of common stock

Neuralstem, Inc. announced today that it has entered into agreements with certain institutional and accredited investors for a registered direct placement of 5,200,000 shares of common stock at a price of $1.00 per share for aggregate gross proceeds of $5,200,000.

6 Feb 2012

Alnylam receives U.S. patent allowance for LNP platform

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application number 12/813,448, covering the company's proprietary second generation lipid nanoparticle (LNP) platform, including the "MC3" lipid.

30 Jan 2012

Prosensa secures €23M in new equity financing

Prosensa, the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet needs, announced today that it has raised €23 million in new equity financing.

25 Jan 2012

Huntington's Disease News and Research

Latest Huntington's Disease News and Research

Positive results from Alnylam’s ALN-PCS Phase I trial on severe hypercholesterolemia

Huntington’s disease may protect against cancer: Study

Technique developed to identify rogue clustering proteins in brain diseases

Novel technique rapidly identifies and tracks location of diseased proteins inside cells

Alnylam commences dosing in ALN-TTR02 Phase I clinical trial for TTR-mediated amyloidosis

GABA neurons could help restore muscle coordination deficits of Huntington's

Measuring wellbeing in Huntington’s disease

Nuvilex overcomes fundamental challenges faced in stem cell therapy

WUSTL scientists to decode DNA of 99 patients with rare diseases

Researchers refute widely accepted hypothesis about causative step in ALS

Researchers discover mechanism by which lead alters nerve cells in the brain

Helmholtz Association grant for research on diseases caused by protein misfolding

New drug for Huntington's disease might operate via previously unknown mechanisms of action

New Huntington's drug might operate via previously unknown mechanisms of action

New potential therapy for Huntington disease

Alnylam commences underwritten public offering of 7,000,000 shares of common stock

New cERD method can detect RNAi activity in biological fluids

Neuralstem announces registered direct placement of 5,200,000 shares of common stock

Alnylam receives U.S. patent allowance for LNP platform

Prosensa secures €23M in new equity financing

eBook: Advancing neurodegenerative research with iPSC-derived microglia models eBook

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Huntington's Disease News and Research

Latest Huntington's Disease News and Research

eBook: Advancing neurodegenerative research with iPSC-derived microglia models eBook

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Newsletters you may be interested in